Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2009

Axikin Taps Proteros for Fragment-Based Lead Discovery in Inflammatory Diseases

  • Axikin Pharmaceuticals signed on Proteros Fragments to discover customized lead compounds for the treatment of inflammatory diseases. Proteros aims to generate multiple advanced lead molecules that inhibit a target protein supplied by Axikin.

    In the initial stages of the program Proteros will solve the x-ray structure of this protein, develop assays, and identify active fragments from its library. It will also determine the binding mode of the fragments to the target protein using its crystallography platform. In the second phase, Proteros’ chemists will evolve the selected fragments into a lead series meeting specific criteria including demonstrated activity and selectivity.

    Proteros will receive research funding and success milestone payments including fees if compounds arising out of the collaboration advance to clinical development.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »